Dr. De-chu Chris Tang is the Founder CEO of VaxDome Inc. He and his associates were the first to have developed DNA vaccines, skin-patch vaccines, antiviral/vaccine hybrids and in vivo cytotoxicity assay, etc. Dr. Tang obtained his PhD degree from Indiana University. He founded Vaxin Inc. when he was an assistant professor at University of Alabama at Birmingham. VaxDome Inc. is located on University of North Texas Health Science Center campus, with a focus on the development of an antiviral vaccine/vaccine potentiator package without constraints imposed by viral mutations; as well as a tissue resident cellular immunity assay with missing-in-action T cells excluded.

Prof. Rouse is a native of England where he completed his education through a BVSc honors degree. Graduate education in Canada with MSc in Virology and PhD in immunology Postdoctoral fellowship at Walter and Eliza Hall of Medical Research in Melbourne Australia in Cellular Immunology 1970-72.Established research Program at University of Saskatchewan on Viral immunology supported by Medical Research Council of Canada. Moved to College of Veterinary Medicine University of Tennessee in 1977 where he remains as the Lindsay Young Distinguished Professor. Took several mainly sabbaticals, including one with Peter Doherty (another veterinarian) in Canberra and Hermann Wagner for one year in Mainz, Germany Worked on the immunology of herpes virus infections supported continuously by multiple NIH grants until the lad was closed in Dec 2022.Published >470 research articles and reviews with and h index 91 and won several Research Achievement awards. Trained 80 PhD and postdoctoral fellows most of whom he stays in contact and occasionally writes reviews on topics in Viral Immunology.

For more than twenty years, Soto has dedicated her career to being a leading advocate for Latino immigrant equality, inclusion and health equity in Colorado and throughout the nation. From working with teen parent programs and serving on the Colorado Vaccine Equity Task Force, to promoting health equity at the American Diabetes Association, Soto has pioneered a wide range of programming designed to empower marginalized communities. Her advocacy efforts have appeared in publications throughout Colorado, as well as NPR, Time magazine, the American Public Health Association Public Health, Religion and Spirituality Bulletin, and a new documentary from the Colorado Cross-Disability Coalition. Today, Soto is proud to continue to provide consulting and education services to partners and agencies throughout Colorado and the United States as CEO and founder of Julissa Soto Latino Health Equity Consulting.

Dr. Parimal R. Desai retired in May 2023 as Vice President of the Merck Manufacturing Division in West Point, Pennsylvania, USA. At Merck, he established a large molecule product development organization and played a crucial role in the accelerated launch of Keytruda, a groundbreaking immune-oncology drug. Over the past decade, his leadership was instrumental in commercializing life-saving vaccines against diseases such as Ebola, Dengue, Pneumococcal virus, HPV, CMV, and COVID-19, leading to the licensure of Gardasil 9, Vaxelis, Vaxneuvance, and Ervebo Ebola virus vaccines. Before joining Merck in 2010, Dr. Desai held significant positions at Pfizer, Wyeth, and American Cyanamid. With over 33 years of experience, he directed global product development functions, successfully developing and launching more than two dozen pharmaceuticals and vaccines. He also served as CEO of Hilleman Laboratories in India and remains an advisor to the Hilleman Labs CEO and Board of Directors. Notably, the HILLCHOL Cholera vaccine, developed by Hilleman Labs, was launched in August 2024 by Bharat Biotech. Dr. Desai earned his Ph.D. in Biochemistry from Penn State University, USA.

Haluskova Balter Ivana , MD,MBA, France French Medical ID professional specialized in infectious diseases, internal medicine, certified in Immunology and Pediatric, MBA vaccinology and years of clinical practice. Certified in Health and Diplomacy with Lived multi-country medical “field “experience in Southeast Asia (India in particular), West/Central/East Europe. Over 17 years of experience in senior medical lead positions in pharmaceutical research. Member of World alliance against antibiotic resistance and French immunology society (SFI) administrative boards and several international academic societies with focus at innovation of R&D. reflecting immunology and genetic variability, role of immunologic approach for treatment and diagnostic to tackle problem of resistance and role of microbiota to empower host immune response with extensive clinical application. Member of international advisory group (CHD India) in order to attract attention to crucial importance of health issues for sustainable economic development and security. Years of expertise to work on project related to global health more focused at Eurasia and Asia (India in particular).

Suzan Farhang-Sardroodi is a Research Associate at the Department of Pharmacology and Toxicology, University of Toronto. With a Ph.D. in Physics, specializing in Evolutionary Dynamics from the University of Zanjan, and enhanced by an exchange semester at the University of Waterloo, she later ventured into Postdoctoral Research. Her postdoc endeavours spanned quantitative oncology at the Biomathematics and Fluids Group at Toronto Metropolitan University, and quantitative immunology at the departments of Mathematics and Statistics at York University, University of Manitoba, and Université de Montréal. Her research is focused on creating predictive and mechanistic models to understand the human immune response to various diseases and to tailor treatment strategies accordingly. Her recent ventures into clinical pharmacology have led her to explore the realms of pharmacometrics and quantitative systems pharmacology/Toxicology (QSP/QST), aiming to refine drug development and therapy.

Dr. Ian James Martins is an Editor/Reviewer for Open Acess Pub/MDPI journals, Frontiers, Scientific Reports (Nature), PLOS ONE and various other international journals. Advisory Board Member for Photon Journal. His expertise has earned him a position on the Advisory Board for Photon Journal and the honor of being a Top Peer Reviewer, ranking in the top 1% in 22 Essential Science Indicators fields. Dr. Martins has served as Chief Editor for several prestigious journals in the realms of diabetes, neuroscience, nutrition, endocrinology, and metabolism. With an impressive h-index of 132 and over 15,474 citations in the past 27 years, he has been awarded 182 international certificates and boasts a Research Gate score higher than 97.5% of global scientists.

Ike James is a distinguished professional at the Medicines Patent Pool (MPP), where he serves as the Head of Technology Transfer. He is a key member of the Senior Management Team and oversees MPP's initiatives in technology transfer, local production in low- and middle-income countries, and its role in the ACT-A/COVAX Manufacturing Workforce. Before joining MPP, Ike held technical leadership roles at Biovac, Aspen Pharmacare, and Lonza, accumulating approximately 16 years of experience in the pharmaceutical industry. His expertise includes product development, technology transfer, process validation of small molecules and biological products, and operationalizing new manufacturing facilities. Ike earned his PhD in Chemical Engineering from Stellenbosch University, South Africa.

Professor Ljudmila Stojanovich is a distinguished medical researcher specializing in Autoimmune Rheumatic diseases, notably Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Since earning her Ph.D. in Medicine in 1999, she has authored three monographs and over 250 articles in her field, earning global recognition for her expertise. She serves on editorial boards of prestigious journals like LUPUS (London) and The Journal of Rheumatology, and actively contributes to international projects and committees, including the European Forum on Antiphospholipid Antibodies. Prof. Stojanovich is a sought-after speaker at congresses and has received accolades such as the GRANT 2015 from the European Stroke Conference. Committed to education, she mentors post-doctoral students and supports initiatives like the LUPUS ACADEMY EASTERN EUROPEAN ROADSHOW. With an h-index of 34 and over 4,700 citations, her impact on medical research and practice is profound and enduring.

Corrado Angelini, MD, is a full professor of neurology at the University of Padova, Italy, where he also serves as coordinator of the PhD program in neurosciences and director of the Neurology Residency Program and the Department of Neurosciences Neuromuscular Center. Dr. Angelini earned his medical degree from the University of Padova and completed two fellowships with the Muscular Dystrophy Association, a research fellowship in 1972 at the Mayo Clinic, where he was a resident in Neurology and a senior fellowship in 1978 at University of California Los Angeles. In 1983 and 1988 was a Visiting Professor at University of Colorado, Denver and University of Boston . His major research interests are primary biochemical defects in inherited neuromuscular diseases, clinical trials, pathophysiology of muscle dystrophies, myasthenia gravis, congenital muscle diseases, carnitina, lipid metabolism and disuse muscle atrophy and sarcopenia.

Dr. Vincenzo Alfano holds currently the position of Assistant Professor in Political Economy at University of Napoli Parthenope. He is also associate to Institute for the Mediterranean of the Italian National Research Council, to the Center for Economic Studies – /CESifo/, is research fellow for Global Labour Organization/– GLO/, and fellow for Italy’s National University Centre for Applied Economic Studies - /CiMET/. Moreover, he serves as a board member of several scientific journals, and is the Academic Editor of /Plos One/.Dr. Alfano has broad research interests, going from health economics and public health to the economic impact of religion and sports economics.

Jigjidsuren Chinburen is a distinguished Member of the Mongolian Parliament and a highly respected State Honored Physician of Mongolia, known for his significant contributions to healthcare policy and legislative reform. With over two decades of expertise in oncology and hepato-pancreato-biliary surgery, Dr. Chinburen has been instrumental in advancing patient care and surgical techniques. He previously served as the General Director of the National Cancer Center Mongolia, overseeing strategic operations and enhancing healthcare services. Dr. Chinburen's leadership extends to his role as the Chief of the Advisory Oncology Committee at the Ministry of Health, where he spearheaded the development of national cancer treatment guidelines. He is also an active educator and researcher, holding a Ph.D. from Tokyo Women’s Medical University and serving as a Professor at the Health Science University of Mongolia. Dr. Chinburen's dedication to medical innovation is evidenced by his numerous publications and presentations on liver surgery and cancer treatment outcomes. He is a prominent figure in international medical circles, holding honorary memberships in prestigious surgical associations and contributing significantly to the advancement of surgical practices in Mongolia and beyond.

Atef Fawaz is a distinguished leader in healthcare management, currently serving as the Executive Director at eHealth Africa (eHA). With over a decade of experience, Atef has honed his skills in operations management, beginning his journey as Operations Manager and COO at Electronic Connections Ltd. in Kano. Since joining eHA in November 2012, he has played a pivotal role in improving healthcare accessibility and quality in underserved regions. Notable achievements include establishing Polio Emergency Operations Centers in Nigeria, leading Ebola response efforts, and expanding Polio control rooms across Africa. Atef’s humanitarian contributions have earned him recognition, including a service award from Rotary International and a nomination to the Kano State COVID-19 Task Force. With over a decade of experience in operations management, he excels in strategic planning and program success.

Dr. Nemat Khansari, a prominent immunologist, began his journey at Tehran University, earning his D.V.M. in 1970. After practicing in Tehran, he moved to the U.S. in 1975, where he achieved his M.S. and Ph.D. in Immunology from the University of Illinois by 1981. His post-doctoral work at the Medical Sciences University of South Carolina led to significant publications. As the Cellular Division Director at IMREG, Inc., he spearheaded research on HIV immunomodulators. He later taught and conducted aging immunology research at North Dakota State University. Returning to Iran in 1990, Dr. Khansari contributed to the Iranian Pasteur Institute and the Blood Bank, and taught at Tehran Medical School until 2009. Post-retirement, he directed the NK-Immunotherapy Laboratory in California and the medical Laboratory at Gandhi Hotel Hospital in Tehran. His scholarly contributions include 54 articles in international journals, 20 in Iranian journals, and 12 books on Biotechnology and Immunology.